使用950例病例进行边缘状态的单变量生存模型显示,阳性边缘与PFI(p < 0.001)和OS(p = 0.006)作为终点的生存率显著相关(图1)。除了边缘状态外,分期、TNM、PAM50亚型和激素受体(雌激素受体(ER)、孕激素受体(PR))状态与疾病进展显著相关(表3)。在对组织学进行生存模型分析时,发现粘液性癌与导管癌相比具有显著的生...
For women with HER2-positive breast cancers, the targeted drugtrastuzumab(Herceptin) has been shown to dramatically reduce the risk of the cancer coming back. It‘s standard treatment to give this medication along withchemotherapyafter surgery to people with breast cancer that’s spread to other ar...
In this report, we present the case of a female patient with relapsed and metastatic breast cancer, whose histology transformed from initially triplenegative to Luminal-B type (HER2 positive) (i.e., ER, PR, and HER2 positive). She underwent systematic chemotherapy, ...
Purpose. Breast cancer, the second leading cause of cancer mortality among women in the U.S., following lung cancer is described and the number of treatment options for patients with breast cancer, which has been accompanied by a trend toward declining cancer mortality, is reviewed.Summary. Desp...
The risk for patients with weakly ER-positive breast cancer should not be underestimated.doi:10.1007/s10549-018-4948-yRyu Jai MinChoi Hee JunKim IsaacLee Se KyungYu JonghanKim Jee-EunKang Byeong-ilLee Jeong EonNam Seok JinKim Seok WonSpringer USBreast Cancer Research and Treatment...
BreastCancerBreastCancer 2 "PinkRibbon"hasbeenasthe worldrecognizedidentification Breastcancerprevention activities,publicityfor"early prevention,earlydetection,early treatment"thisinformation. “粉红丝带”作为全球乳腺癌防治活动的公认标识,用于宣传“及早预防,及早 ...
Drugs used after and in addition to surgery are calledadjuvant therapy(辅助治疗). Chemotherapy or other types of therapy prior to surgery are calledneoadjuvant therapy(新辅助治疗). There are currently three main groups of medica...
The image shows a molecular([m?‘lekj?l?]) model(分子模型) of an estrogen receptor(雌激素受体).;Hormone Therapy for Breast Cancer(乳腺癌的激素疗法) Hormone therapy is an effective treatment for women with ER-positive or PR-positive breast cancer(激素疗法对ER阳性或PR阳性乳腺癌特别有效). ...
Most types of breast cancer (up to 70 per cent) are positive for ER or PR, or both. Such cancers tend to be slower-growing and less aggressive, and patients are, therefore, more likely to have a better long-term outcome. These cancers are usually treated with hormonal therapy such as ...
Estrogen receptor (ER)-positive breast cancer represents approximately 70% of all breast cancers and the selec- tive ER modulator (SERM), tamoxifen, remains the mainstay of treatment in pre-menopausal women [1]. Although several studies have established the role of tamoxifen in significantly reduc...